Company: AZN
Filing Date: 2025-07-24
Form Type: 6-K
Source: 0001654954-25-008413
Chunk: 3

Company: ASTRAZENECA PLC
Filing Date: 2025-07-24
Form: 6-K
Chunk 3
---
 week 26 along with multiple secondary endpoints evaluating improvement in disease-related measures. 7

Patients who completed the randomised controlled treatment period were eligible to continue into an open-label extension period evaluating the safety and efficacy of gefurulimab, which is ongoing. 7

#### Alexion
Alexion, AstraZeneca Rare Disease, is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and delivery of life-changing medicines. A pioneering leader in rare disease for more than three decades, Alexion was the first to translate the complex biology of the complement system into transformative medicines, and today it continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities. As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US.

#### AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca .

#### Contacts
For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

#### References
1. Jung-Plath W, et al. Assessment of myasthenia gravis patients' quality of life. The Journal of Neurological and Neurosurgical Nursing . 2023;12(2):74-83.

2. Catalin J, et al. Clinical presentation of myasthenia gravis. Thymus . 2019.

3. Farid ZR, et al. Factors affecting generalization of ocular myasthenia gravis. Sriwijaya Journal of Ophthalmology . 2020;3(2):48-54.

4. Lazaridis K, et al. Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol. 2020;11:596981.

5. Huang YF, et